CL2018002797A1 - Receptores quiméricos y métodos de uso de los mismos. - Google Patents
Receptores quiméricos y métodos de uso de los mismos.Info
- Publication number
- CL2018002797A1 CL2018002797A1 CL2018002797A CL2018002797A CL2018002797A1 CL 2018002797 A1 CL2018002797 A1 CL 2018002797A1 CL 2018002797 A CL2018002797 A CL 2018002797A CL 2018002797 A CL2018002797 A CL 2018002797A CL 2018002797 A1 CL2018002797 A1 CL 2018002797A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- chimeric receptors
- cll
- union
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317068P | 2016-04-01 | 2016-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018002797A1 true CL2018002797A1 (es) | 2020-06-12 |
Family
ID=59960746
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002797A CL2018002797A1 (es) | 2016-04-01 | 2018-10-01 | Receptores quiméricos y métodos de uso de los mismos. |
| CL2019002310A CL2019002310A1 (es) | 2016-04-01 | 2019-08-14 | Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797) |
| CL2020002677A CL2020002677A1 (es) | 2016-04-01 | 2020-10-15 | Receptores quiméricos y metodos de uso de los mismos(divisional de solicitud 2310-2019) |
| CL2021001750A CL2021001750A1 (es) | 2016-04-01 | 2021-06-30 | Receptores quiméricos y metodos de uso de los mismos (divisional solicitud 2677-2020) |
| CL2022001873A CL2022001873A1 (es) | 2016-04-01 | 2022-07-08 | Receptores quiméricos y metodos de uso de los mismos |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002310A CL2019002310A1 (es) | 2016-04-01 | 2019-08-14 | Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797) |
| CL2020002677A CL2020002677A1 (es) | 2016-04-01 | 2020-10-15 | Receptores quiméricos y metodos de uso de los mismos(divisional de solicitud 2310-2019) |
| CL2021001750A CL2021001750A1 (es) | 2016-04-01 | 2021-06-30 | Receptores quiméricos y metodos de uso de los mismos (divisional solicitud 2677-2020) |
| CL2022001873A CL2022001873A1 (es) | 2016-04-01 | 2022-07-08 | Receptores quiméricos y metodos de uso de los mismos |
Country Status (33)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11505613B2 (en) | 2016-04-01 | 2022-11-22 | Kite Pharma, Inc. | BCMA binding molecules and methods of use thereof |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3013407A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| AU2017242893A1 (en) | 2016-03-31 | 2018-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indole derivatives as dengue viral replication inhibitors |
| PL3436079T3 (pl) | 2016-04-01 | 2021-12-20 | Kite Pharma, Inc. | Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania |
| PE20190356A1 (es) | 2016-04-01 | 2019-03-07 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| KR102359766B1 (ko) | 2016-04-01 | 2022-02-07 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체 |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JP7203764B2 (ja) | 2017-05-22 | 2023-01-13 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | デングウイルス複製阻害剤としての置換インドリン誘導体 |
| DK3630724T3 (da) | 2017-05-22 | 2021-07-26 | Janssen Pharmaceuticals Inc | Substituerede indolinderivater som inhibitorer af virusreplikation af denguevirus |
| US11390655B2 (en) * | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| CN109609533B (zh) * | 2017-12-27 | 2020-07-10 | 赛德特生物科技开发有限公司 | 基于人源化cd276抗体的car慢病毒表达载体构建及其应用 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| AU2019318135A1 (en) * | 2018-08-10 | 2021-03-04 | Sangamo Therapeutics France | New car constructs comprising TNFR2 domains |
| CN113039205B (zh) * | 2018-10-26 | 2024-03-22 | 科济生物医药（上海）有限公司 | 靶向cll1的抗体及其应用 |
| KR20210138574A (ko) | 2019-03-01 | 2021-11-19 | 알로젠 테라퓨틱스 인코포레이티드 | Dll3 표적화 키메라 항원 수용체 및 결합제 |
| CN114026118A (zh) * | 2019-05-07 | 2022-02-08 | 里兰斯坦福初级大学理事会 | 通过铰链结构域增强多肽和嵌合抗原受体 |
| US20220257796A1 (en) | 2019-07-02 | 2022-08-18 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
| CA3154389A1 (en) * | 2019-09-13 | 2021-03-18 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting cd371 and uses thereof |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| CN113045658B (zh) | 2020-12-11 | 2021-12-24 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| CN113416713A (zh) * | 2021-05-11 | 2021-09-21 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种重组腺病毒的构建及其应用 |
| CN115521917A (zh) * | 2021-06-25 | 2022-12-27 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| WO2023147331A1 (en) | 2022-01-26 | 2023-08-03 | Mabswitch Inc. | Bispecific molecule with tunable affinity to a targetted antigen |
| TW202340457A (zh) * | 2022-02-28 | 2023-10-16 | 美商凱特製藥公司 | 同種異體治療細胞 |
| EP4577234A1 (en) | 2022-08-26 | 2025-07-02 | Kite Pharma, Inc. | Improving immune cell function |
| GB202214132D0 (en) | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
| GB202301949D0 (en) | 2023-02-10 | 2023-03-29 | Coding Bio Ltd | CLL1 and/or CD33 binding molecules |
| US20240293462A1 (en) * | 2023-03-03 | 2024-09-05 | Trustees Of Boston University | Immune Cell Fusion (ICF) and Uses Thereof |
| US12310988B2 (en) * | 2023-04-18 | 2025-05-27 | Board Of Regents, The University Of Texas System | BCMA chimeric antigen receptors and uses thereof |
| WO2025194098A1 (en) | 2024-03-14 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Engineered immune cells expressing chimeric antigen receptors targeting trop2, and methods of using the same |
| WO2025231376A1 (en) * | 2024-05-03 | 2025-11-06 | Kite Pharma, Inc. | Chimeric receptors binding to cll-1 and methods of use thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6892139B2 (en) | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| NZ543635A (en) * | 2003-06-25 | 2008-05-30 | Crucell Holland Bv | Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2006028785A2 (en) | 2004-09-03 | 2006-03-16 | General Motors Corporation | Aligning method for repeating and non-repeating units in a fuel cell stack |
| WO2007137300A2 (en) | 2006-05-23 | 2007-11-29 | Bellicum Pharmaceuticals, Inc. | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| CA2743669C (en) | 2008-11-24 | 2018-10-16 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | High affinity t cell receptor and use thereof |
| HRP20161194T1 (hr) | 2009-03-10 | 2016-11-04 | Biogen Ma Inc. | Anti-bcma protutijela |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| WO2011061656A1 (en) | 2009-11-17 | 2011-05-26 | Basf Plant Science Company Gmbh | Plants with increased yield |
| US20130052663A1 (en) | 2010-05-05 | 2013-02-28 | Addex Pharma Sa | Chimeric Receptors and Methods for Identifying Agents Exhibiting an Activity on Type 1 Single Pass Transmembrane Receptors |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| US9212229B2 (en) | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| AU2012209103B2 (en) | 2011-01-26 | 2015-12-03 | Takeda Pharmaceutical Company Limited | Methods and compositions for the synthesis of multimerizing agents |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| PH12013502421A1 (en) | 2011-05-27 | 2014-01-06 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| DE102012204596A1 (de) | 2012-03-22 | 2013-09-26 | Ford Global Technologies, Llc | Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs |
| CA3209571A1 (en) | 2012-03-23 | 2013-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| PL2953972T3 (pl) | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
| WO2014124143A1 (en) | 2013-02-06 | 2014-08-14 | Anthrogenesis Corporation | Modified t lymphocytes having improved specificity |
| LT2956175T (lt) | 2013-02-15 | 2017-12-11 | The Regents Of The University Of California | Chimerinis antigeno receptorius ir jo panaudojimo būdai |
| KR20150131218A (ko) | 2013-03-14 | 2015-11-24 | 벨리쿰 파마슈티컬스, 인크. | T 세포 증식의 제어 방법 |
| KR102238226B1 (ko) | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| AU2014352638B2 (en) | 2013-11-25 | 2018-08-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control HIV infection |
| US20160376375A1 (en) | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| PT3102609T (pt) | 2014-02-04 | 2024-10-23 | Us Health | Métodos de produção de células t autólogas úteis para o tratamento de malignidades das células b e de outros cancros e respetivas composições |
| CN106132423B (zh) | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| CN107109420A (zh) * | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| SG10201900455YA (en) | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| WO2016044811A1 (en) | 2014-09-19 | 2016-03-24 | City Of Hope | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2 |
| KR20170083534A (ko) | 2014-09-19 | 2017-07-18 | 리제너론 파마슈티칼스 인코포레이티드 | 키메라 항원 수용체 |
| KR102558502B1 (ko) | 2014-12-05 | 2023-07-20 | 시티 오브 호프 | Ｃｓ1 표적화된 키메라 항원 수용체-변형된 ｔ 세포 |
| NZ733025A (en) | 2014-12-12 | 2022-01-28 | 2Seventy Bio Inc | Bcma chimeric antigen receptors |
| JP6921001B2 (ja) | 2015-04-13 | 2021-08-18 | ファイザー・インク | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
| ES3012402T3 (en) | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| PE20190201A1 (es) | 2016-04-01 | 2019-02-05 | Amgen Inc | Receptores quimericos de flt3 y metodos de uso de los mismos |
| PL3436079T3 (pl) | 2016-04-01 | 2021-12-20 | Kite Pharma, Inc. | Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania |
| US10689450B2 (en) | 2016-04-01 | 2020-06-23 | Kite Pharma, Inc | BCMA binding molecules and methods of use thereof |
| PE20190356A1 (es) | 2016-04-01 | 2019-03-07 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
-
2017
- 2017-03-31 PE PE2018001934A patent/PE20190356A1/es unknown
- 2017-03-31 MA MA43603A patent/MA43603A1/fr unknown
- 2017-03-31 RS RS20221024A patent/RS63735B1/sr unknown
- 2017-03-31 KR KR1020237040899A patent/KR102731644B1/ko active Active
- 2017-03-31 AR ARP170100821A patent/AR108066A1/es unknown
- 2017-03-31 CA CA3019650A patent/CA3019650C/en active Active
- 2017-03-31 UA UAA201809953A patent/UA123276C2/uk unknown
- 2017-03-31 PT PT177768595T patent/PT3436030T/pt unknown
- 2017-03-31 EP EP22191077.1A patent/EP4180449A1/en active Pending
- 2017-03-31 KR KR1020217021089A patent/KR20210089262A/ko not_active Ceased
- 2017-03-31 CR CR20180480A patent/CR20180480A/es unknown
- 2017-03-31 CN CN202110248927.7A patent/CN113150170B/zh active Active
- 2017-03-31 US US15/476,699 patent/US10597456B2/en active Active
- 2017-03-31 IL IL316403A patent/IL316403A/en unknown
- 2017-03-31 HR HRP20221348TT patent/HRP20221348T1/hr unknown
- 2017-03-31 MY MYPI2018703599A patent/MY197669A/en unknown
- 2017-03-31 MX MX2018012019A patent/MX2018012019A/es unknown
- 2017-03-31 IL IL262041A patent/IL262041B2/en unknown
- 2017-03-31 KR KR1020227039755A patent/KR102608405B1/ko active Active
- 2017-03-31 LT LTEPPCT/US2017/025573T patent/LT3436030T/lt unknown
- 2017-03-31 SI SI201731265T patent/SI3436030T1/sl unknown
- 2017-03-31 KR KR1020207015941A patent/KR20200068750A/ko not_active Ceased
- 2017-03-31 PE PE2020001605A patent/PE20211418A1/es unknown
- 2017-03-31 SM SM20220444T patent/SMT202200444T1/it unknown
- 2017-03-31 AU AU2017240788A patent/AU2017240788B2/en active Active
- 2017-03-31 HU HUE17776859A patent/HUE060645T2/hu unknown
- 2017-03-31 EP EP17776859.5A patent/EP3436030B1/en active Active
- 2017-03-31 JP JP2018551953A patent/JP2019513370A/ja active Pending
- 2017-03-31 CN CN202511224360.4A patent/CN121108368A/zh active Pending
- 2017-03-31 UA UAA201909739A patent/UA128781C2/uk unknown
- 2017-03-31 KR KR1020257007542A patent/KR20250039495A/ko active Pending
- 2017-03-31 PE PE2019002307A patent/PE20200400A1/es unknown
- 2017-03-31 ES ES17776859T patent/ES2930058T3/es active Active
- 2017-03-31 SG SG10201912519VA patent/SG10201912519VA/en unknown
- 2017-03-31 BR BR112018070260A patent/BR112018070260A2/pt active Search and Examination
- 2017-03-31 KR KR1020187031572A patent/KR102120815B1/ko active Active
- 2017-03-31 PL PL17776859.5T patent/PL3436030T3/pl unknown
- 2017-03-31 CN CN201780022074.7A patent/CN109641008B/zh active Active
- 2017-03-31 SG SG11201808595WA patent/SG11201808595WA/en unknown
- 2017-03-31 KR KR1020247037911A patent/KR102779944B1/ko active Active
- 2017-03-31 CA CA3177398A patent/CA3177398A1/en active Pending
- 2017-03-31 CR CR20210084A patent/CR20210084A/es unknown
- 2017-03-31 EA EA201891992A patent/EA201891992A1/ru unknown
- 2017-03-31 WO PCT/US2017/025573 patent/WO2017173384A1/en not_active Ceased
- 2017-03-31 DK DK17776859.5T patent/DK3436030T3/da active
- 2017-04-05 TW TW109145084A patent/TWI792123B/zh active
- 2017-04-05 TW TW106111224A patent/TW201803896A/zh unknown
- 2017-04-05 TW TW109107507A patent/TWI714470B/zh active
- 2017-04-05 TW TW112101087A patent/TWI855499B/zh active
-
2018
- 2018-10-01 CO CONC2018/0010547A patent/CO2018010547A2/es unknown
- 2018-10-01 CL CL2018002797A patent/CL2018002797A1/es unknown
- 2018-10-01 PH PH12018502113A patent/PH12018502113A1/en unknown
- 2018-10-01 MX MX2023002556A patent/MX2023002556A/es unknown
-
2019
- 2019-08-14 CL CL2019002310A patent/CL2019002310A1/es unknown
- 2019-10-21 US US16/658,480 patent/US20200115457A1/en not_active Abandoned
-
2020
- 2020-06-15 AU AU2020203990A patent/AU2020203990A1/en not_active Abandoned
- 2020-09-11 JP JP2020152515A patent/JP7134204B2/ja active Active
- 2020-10-15 CL CL2020002677A patent/CL2020002677A1/es unknown
-
2021
- 2021-06-30 CL CL2021001750A patent/CL2021001750A1/es unknown
-
2022
- 2022-07-08 CL CL2022001873A patent/CL2022001873A1/es unknown
- 2022-08-30 JP JP2022136417A patent/JP7451627B2/ja active Active
-
2023
- 2023-03-03 US US18/178,086 patent/US20230331855A1/en active Pending
- 2023-07-24 AU AU2023208077A patent/AU2023208077A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033511A patent/JP7673272B2/ja active Active
-
2025
- 2025-04-23 JP JP2025071243A patent/JP2025111619A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11505613B2 (en) | 2016-04-01 | 2022-11-22 | Kite Pharma, Inc. | BCMA binding molecules and methods of use thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002797A1 (es) | Receptores quiméricos y métodos de uso de los mismos. | |
| CL2018002792A1 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos. | |
| CL2023000895A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| MX2024006564A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| MX2017000419A (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
| MX2018003410A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
| MX2017005920A (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| MX386587B (es) | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| MX393455B (es) | Anticuerpos anti-cd40 y sus usos. | |
| CL2023003182A1 (es) | Receptores químericos de steap1 y métodos de uso de los mismos | |
| MX372675B (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| MX2020001223A (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. | |
| BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
| CL2021001441A1 (es) | Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos (divisional de la solicitud no. 201802932) | |
| CL2017001172A1 (es) | Anticuerpos anti-interleukin-33 y sus usos |